Program
migalastat
Also written as “Lucerastat”, “migalastat HCl” and “migalastat HCl 150 mg”.
Its studies are mostly in Fabry Disease, led by 2 companies.
Drug pageMigalastat: every studyAll 24 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioMarin Pharmaceutical | 172 open or running | phase 3since Jun 19, 2009 | Sep 13, 2005 | Dec 31, 2026phase 3 · NCT04020055 |
| Idorsia Pharmaceuticalsits history only | 71 open or running | phase 3since Jan 16, 2018 | Oct 24, 2016 | Feb 13, 2029phase 3 · NCT07778667 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of BioMarin Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Sep 13, 2005.
- Mar 17, 2006Phase 2 study in Fabry DiseaseNCT00304512 · 9 enrolled · United States, Australia, Brazil and more
- Sep 5, 2007Phase 2 study in Fabry DiseaseNCT00526071 · 23 enrolled · United States, Australia, Brazil and more
- Jun 19, 2009Phase 3 study in Fabry DiseaseNCT00925301 · 67 enrolled · United States, Argentina, Australia and more
- Sep 7, 2010Phase 2 study in Fabry DiseaseNCT01196871 · 20 enrolled · United States, Australia, Belgium and more
- Oct 6, 2010Phase 3 study in Fabry DiseaseNCT01218659 · 68 enrolled · United States, Australia, Austria and more
- Oct 20, 2011Phase 1 study in Fabry DiseaseNCT01489995 · 20 enrolled · United States
- Oct 20, 2011Phase 3 study in Fabry DiseaseNCT01458119 · 85 enrolled · United States, Argentina, Australia and more
- Nov 10, 2011Phase 1 study in Fabry DiseaseNCT01853852 · 14 enrolled · Australia
- Mar 6, 2014Phase 1 study in Fabry DiseaseNCT02082327 · 31 enrolled · Netherlands
- Jul 17, 2014Phase 3 study in Fabry DiseaseNCT02194985 · 84 enrolled · United States, Argentina, Australia and more
- Apr 9, 2018Phase 3 study in Fabry DiseaseNCT03500094 · 22 enrolled · United States, United Kingdom
- Jun 24, 2019Phase 3 study in Fabry DiseaseNCT04020055 · 14 enrolled · United States, Australia, Japan and more
- Jul 30, 2019Phase 3 study in Fabry DiseaseNCT04049760 · 16 enrolled · United States, United Kingdom
- Mar 13, 2025Phase 3 study in Fabry DiseaseNCT06904261 · 8 planned · United States, Belgium, Germany and more
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Fabry DiseaseNCT04020055
- Dec 2027Primary completion: phase 3 study in Fabry DiseaseNCT06904261
TargetBeta
“Alpha-galactosidase A stabiliser; Alpha-galactosidase A stabiliser”ChEMBL 37, by rule
Studies
All 17 BioMarin Pharmaceutical leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06904261Fabry Disease · United States, Belgium, Germany and more | 3 | Recruiting | Dec 2027 | 8 |
| NCT04049760Fabry Disease · United States, United Kingdom | 3 | Completed | Nov 29, 2024 | 16 |
| NCT04020055Fabry Disease · United States, Australia, Japan and more | 3 | Active, not recruiting | Dec 31, 2026 | 14 |
| NCT03500094Fabry Disease · United States, United Kingdom | 3 | Completed | Feb 2, 2021 | 22 |
| NCT02194985Fabry Disease · United States, Argentina, Australia and more | 3 | Completed | Oct 23, 2019 | 84 |
| NCT02082327Fabry Disease · Netherlands | 1 | Completed | Jun 2014 | 31 |
| NCT01853852Fabry Disease · Australia | 1 | Completed | Dec 2011 | 14 |
| NCT01489995Fabry Disease · United States | 1 | Completed | Dec 2011 | 20 |
| NCT01458119Fabry Disease · United States, Argentina, Australia and more | 3 | Terminated | Feb 17, 2016 | 85 |
| NCT01218659Fabry Disease · United States, Australia, Austria and more | 3 | Completed | May 27, 2014 | 68 |
| NCT01196871Fabry Disease · United States, Australia, Belgium and more | 2 | Completed | Oct 9, 2012 | 20 |
| NCT00925301Fabry Disease · United States, Argentina, Australia and more | 3 | Completed | Jun 12, 2012 | 67 |
| NCT00526071Fabry Disease · United States, Australia, Brazil and more | 2 | Terminated | Sep 8, 2012 | 23 |
| NCT00304512Fabry Disease · United States, Australia, Brazil and more | 2 | Completed | May 9, 2008 | 9 |
| NCT00283959Fabry Disease · Australia, Brazil | 2 | Completed | May 8, 2008 | 4 |
| NCT00283933Fabry Disease · France, United Kingdom | 2 | Completed | Mar 12, 2008 | 5 |
| NCT00214500Fabry Disease · United States | 2 | Completed | Jan 29, 2008 | 9 |
How it is read
Names in the registry
- “Lucerastat”, 6 entries
- “migalastat HCl”, 5 entries
- “migalastat HCl 150 mg”, 3 entries
- “migalastat hydrochloride”, 3 entries
- “Migalastat HCl 20 mg”, 1 entry
Conditions, from the studies’ own filings
- Fabry Disease, 20 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.